Key Highlights

  • Net sales were USD 9.69 million against an estimate of USD 10.92 million and USD 8.69 million last year.
  • Loss per share was USD 0.13 against an estimate of a USD 0.27 loss and USD 0.40 last year.
  • Gross Margin was 88.5% against 86.0%, and the net loss was USD 1.34 million against USD 3.41 million.
  • Cash and marketable securities were USD 7.5 million, and the company disclosed substantial doubt about continuing as a going concern.

electroCore, Inc. (NASDAQ:ECOR) sells prescription nerve stimulation devices. Beginning in August 2026, the company moved all prescription sales to the Department of Veterans Affairs and the Department of Defense through its distribution agreement with Lovell Government Services, which accounted for 62.6% of third quarter net sales.

Strategy and Operations

Prescription gammaCore for primary headache and Quell Fibromyalgia are the two leading products, with Truvaga and TAC-STIM serving the general wellness and human performance markets. The company said the majority of 2026 Revenue continues to come from prescription sales to the VA. Sales to the UK National Health Service under the MedTech Funding Mandate for cluster headache were 4.2% of revenue in the quarter, and the company plans to keep using that program through the rest of 2026.

On the regulatory side, the FDA closed an inspection of the Rockaway, New Jersey Facility in May with a Form 483 citing four observations. On October 27, the FDA told the company no written response was required and limited its comments to one observation on medical device reporting procedures, which the company is addressing through a corrective action plan. In October, the company submitted a 510(k) premarket notification seeking clearance of Quell for chronic chemotherapy-induced peripheral neuropathy, a use that holds Breakthrough Device Designation granted in January 2022.

Financial Results

Net sales rose 12% to USD 9.69 million, driven mainly by Quell Fibromyalgia and prescription gammaCore sales to the VA. Gross Profit was USD 8.57 million against USD 7.47 million, with the margin change attributed to product mix. Research and Development expense was USD 0.43 million against USD 0.66 million, and selling, general and administrative expense was USD 9.70 million against USD 9.69 million.

The loss from operations was USD 1.56 million against USD 2.88 million. Other income included a gain of about USD 0.4 million from a settlement of indemnification claims. Over nine months, net sales were USD 28.72 million against USD 22.79 million, and the net loss was USD 9.67 million against USD 10.93 million.

Capital and Funding

Net cash used in Operating Activities was USD 9.36 million over nine months, against USD 6.65 million, which the company tied to higher inventory and the timing of expense payments. Financing provided USD 5.26 million, including USD 4.0 million of net proceeds from at-the-market sales of 505,346 shares.

The company holds a Loan agreement with Avenue Venture Opportunities Fund II for up to USD 12.0 million. Following an extension of the interest-only period, principal repayments begin in September 2027 and are scheduled at USD 1.25 million in 2027, USD 3.75 million in 2028 and USD 2.92 million in 2029. About USD 15.7 million remains available under the sales agreement, within USD 95.9 million of remaining shelf capacity. Management said planned cash resources fall short of requirements for at least the next 12 months, which raises substantial doubt about continuing as a going concern.

Balance Sheet and Cash Markers

Cash and cash equivalents of USD 6.31 million sit alongside marketable securities of USD 1.20 million, a net loss of USD 1.34 million and nine-month cash used in operations of USD 9.36 million. Management named several priorities: continuing targeted investments in sales, Marketing and research and development through the rest of 2026, the Lovell transition for government sales, corrective action on the FDA observation, and the pending 510(k) review for chemotherapy-induced neuropathy.